|
| 37940410 | Lung Cancer in Women: The Past, Present, and Future. | Clin Lung Cancer | 2024 |
| 36264123 | Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON. | Cancer Discov | 2023 |
| 37808694 | Germline mutations and developmental mosaicism underlying <i>EGFR</i>-mutant lung cancer. | medRxiv | 2023 |
| 37521368 | B-Cell Infiltrate in the Tumor Microenvironment Is Associated With Improved Survival in Resected Lung Adenocarcinoma. | JTO Clin Res Rep | 2023 |
| 37903855 | Role of sex in lung cancer risk prediction based on single low-dose chest computed tomography. | Sci Rep | 2023 |
| 37883100 | Improving Eligibility Criteria for Lung Cancer Screening-Promises, Challenges, and Unmet Needs. | JAMA Oncol | 2023 |
| 37934096 | Twenty-year Progress in Lung Cancer Screening: A Marathon, Not a Sprint. | Radiology | 2023 |
| 37533439 | Efficacy and Tolerability of <i>ALK</i>/<i>MET</i> Combinations in Patients With <i>ALK</i>-Rearranged Lung Cancer With Acquired <i>MET</i> Amplification: A Retrospective Analysis. | JTO Clin Res Rep | 2023 |
| 37407818 | Therapy-induced APOBEC3A drives evolution of persistent cancer cells. | Nature | 2023 |
| 37235976 | Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations. | J Clin Oncol | 2023 |
| 37098234 | Expanding the Reach and Grasp of Lung Cancer Screening. | Am Soc Clin Oncol Educ Book | 2023 |
| 36534938 | Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2. | J Clin Oncol | 2023 |
| 36634294 | Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography. | J Clin Oncol | 2023 |
| 34896762 | Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study. | ESMO Open | 2022 |
| 35534623 | Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. | Nat Rev Clin Oncol | 2022 |
| 35637759 | High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience. | JTO Clin Res Rep | 2022 |
| 35524758 | Phase II Study of Cabozantinib in Patients With Bone Metastasis. | Oncologist | 2022 |
| 35357454 | Incidence of Radiation Therapy Among Patients Enrolled in a Multidisciplinary Pulmonary Nodule and Lung Cancer Screening Clinic. | JAMA Netw Open | 2022 |
| 35810553 | Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study. | Eur J Cancer | 2022 |
| 35971001 | Author Correction: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. | Nat Rev Clin Oncol | 2022 |
| 36118132 | Clinicopathologic Characteristics and Outcomes for Patients With <i>KRAS</i> G12D-Mutant NSCLC. | JTO Clin Res Rep | 2022 |
| 35016028 | LTK fusions: A new target emerges in non-small cell lung cancer. | Cancer Cell | 2022 |
| 34887193 | Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib. | Clin Lung Cancer | 2022 |
| 35176458 | ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. | Ann Oncol | 2022 |
| 32755209 | Clinicopathologic and Longitudinal Imaging Features of Lung Cancer Associated With Cystic Airspaces: A Systematic Review and Meta-Analysis. | AJR Am J Roentgenol | 2021 |
| 33685866 | Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung Cancer. | Clin Cancer Res | 2021 |
| 33494925 | A New Era of Protein-Based Assays for Cancer Early Detection. | J Thorac Oncol | 2021 |
| 33545388 | A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. | J Thorac Oncol | 2021 |
| 33610453 | Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression. | Clin Lung Cancer | 2021 |
| 34624218 | Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. | Cancer Cell | 2021 |
| 34301786 | Targeting <i>EGFR</i> Exon 20 Insertions in Non-Small Cell Lung Cancer: Recent Advances and Clinical Updates. | Cancer Discov | 2021 |
| 34273294 | Lung cancer. | Lancet | 2021 |
| 34246791 | Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. | J Thorac Oncol | 2021 |
| 34151132 | Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer. | JCO Precis Oncol | 2021 |
| 33189594 | Clinical and Imaging Features of Non-Small-Cell Lung Cancer in Young Patients. | Clin Lung Cancer | 2021 |
| 33188913 | Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation. | J Thorac Oncol | 2021 |
| 33069888 | Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. | J Thorac Oncol | 2021 |
| 33205053 | Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations. | JTO Clin Res Rep | 2021 |
| 31492767 | Patient Preferences for Use of Archived Biospecimens from Oncology Trials When Adequacy of Informed Consent Is Unclear. | Oncologist | 2020 |
| 35121842 | A bright future for KRAS inhibitors. | Nat Cancer | 2020 |
| 34589988 | Revolving Door of Histologic Transformation-Tumor Heterogeneity Complicating the Management of <i>EGFR</i>-Mutated Lung Adenocarcinoma: A Case of Jekyll and Hyde. | JTO Clin Res Rep | 2020 |
| 31876321 | Integrated, Multidisciplinary Management of Pulmonary Nodules Can Streamline Care and Improve Adherence to Recommendations. | Oncologist | 2020 |
| 31732522 | A Th1/IFNγ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer. | Clin Cancer Res | 2020 |
| 32027846 | Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. | Lancet Oncol | 2020 |
| 31988000 | RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. | J Thorac Oncol | 2020 |
| 31954624 | Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. | Lancet Respir Med | 2020 |
| 31887093 | Imaging Features and Metastatic Patterns of Advanced <i>ALK</i>-Rearranged Non-Small Cell Lung Cancer. | AJR Am J Roentgenol | 2020 |
| 31708389 | Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer. | Clin Lung Cancer | 2020 |
| 33007380 | Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. | Ann Oncol | 2020 |
| 32907839 | Modeling Resistance and Recurrence Patterns of Combined Targeted-Chemoradiotherapy Predicts Benefit of Shorter Induction Period. | Cancer Res | 2020 |